The commercial success of second-generation radiopharmaceuticals in oncology has re-ignited interest in this modality, resulting in a surge of dealmaking and increased venture financing for companies in the field.
Read MoreBack Bay Life Science Advisors examines the commercial and clinical potential of optogenetic therapies from ophthalmology diseases, and oncology to chronic pain and more.
Read More